A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
A legfontosabb adatok
- Ki végzi
- Takeda
- Hol
- Chicago, Dallas, Denver, Durham, Great Neck, Irvine, Macon, New Orleans, Normal, St. Petersburg, The Bronx, Tulsa és Walnut Creek (Egyesült Államok)Mind a 13 helyszín megnézéseMég 8 másik országban, 19 helyszínen
- Azonosító
- Állapot
- Fut, nem toboroz
- Fázis
- 3. fázis
- Résztvevők
- 53 fő vett részt
- Kezdés
- 2024. nov. 4.
- Várható befejezés
- 2028. máj. 16.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- TAK-881
- Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US)
- A regiszteradat frissítve
- 2026. április 8.
Ki vehet részt
- Életkor
- 2 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 11 feltétel megnézéseKevesebb
Ki vehet részt
- Participants who meet ALL of the following criteria are eligible for this study:
- Participant must have completed Study TAK-881-3001 (NCT05755035)
- Participant or, in the case of minors, legally designated representative(s) is/are willing and able to comply with the requirements of the protocol
- Participant or, in the case of minors, legally designated representative(s) has/have provided informed consent/assent (if applicable), including providing consent for use of the investigational medical device (in US sites only), prior to the initiation of any study procedures
Ki nem vehet részt
- Participant was enrolled in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to screening (with the exception of Study TAK-881-3001 [NCT05755035])
- Participant is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
- Participant has a serious medical condition such that the participant's safety or medical care would be impacted by participation in this long-term follow-up study
- New medical condition that developed during participation in Study TAK-881-3001 (NCT05755035), that, in the judgment of the investigator, could increase risk to the participant or interfere with the evaluation of TAK-881 and/or conduct of the study
- Participant is a family member or employee of the investigator or the investigator's site staff
- Participants with potential to become pregnant who meet any one of the following criteria:-; Participant has a positive pregnancy test; Participant does not agree to employ a highly effective form of contraception for the duration of the study
- If participant is pregnant or lactating at the time of screening or intends to become pregnant or begin lactating during the study
Helyszínek itt: Egyesült Államok
Még 8 másik országban, 19 helyszínen
- Rush University Medical Center-Allergy/ Immunology CenterChicago, Egyesült Államok
- Allergy Partners of North TexasDallas, Egyesült Államok
- National Jewish Medical and Research CenterDenver, Egyesült Államok
- Duke Asthma Allergy and Airway CenterDurham, Egyesült Államok
- North Shore-Long Island Jewish Health SystemsGreat Neck, Egyesült Államok
- University of California, Irvine Medical Sciences IIrvine, Egyesült Államok
- Central Georgia Infectious Disease ConsultantsMacon, Egyesült Államok
- Louisiana State University Health Science CenterNew Orleans, Egyesült Államok
- Sneeze, Wheeze, & Itch Associates LLCNormal, Egyesült Államok
- University of South FloridaSt. Petersburg, Egyesült Államok
- Montefiore Medical CenterThe Bronx, Egyesült Államok
- Allergy, Asthma and Immunology CenterTulsa, Egyesült Államok
- Allergy & Asthma Clinical ResearchWalnut Creek, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The main aim of this study is to learn if TAK-881 is safe and well tolerated during long-term use in adults and children with PIDD who are eligible and completed study TAK-881-3001 (NCT05755035).
A teljes eredeti leírásKevesebb
The participants will receive the first dose of TAK-881 immunoglobulin (IgG) infusion at the same dosage as the last dose administered in study TAK-881-3001 (NCT05755035). After the first TAK-881 infusion in study TAK-881-3002, the dosing interval (can be adjusted by participant/caregiver) and/or the dose of TAK-881 can be adjusted by the study doctor to every 2, 3 or 4 weeks at scheduled site visits.
Participants will visit the clinic every 12 weeks until the End of Study (EOS) visit.
A vizsgálat csoportja
- TAK-881A vizsgált kezelés
Epoch 1: Participants who completed study TAK-881-3001 (NCT05755035) and met eligibility criteria will receive TAK-881 using Koru 24 G HlgH Flo subcutaneous (SC) safety needle set (investigational in the US) at the same dose and same treatment interval as at the last infusion in TAK-881-3001 (NCT05755035) at Week 1 and at Weeks 13 and Week 25 of study TAK-881-3002. Epoch 2: Participants with anti-rHuPH20 antibody titer \>=1:160 at any time point during Study TAK-881-3001 (NCT05755035) and/or Study TAK-881-3002 Epoch 1, will continue receiving TAK-881 every 12 weeks for up to Week 121. After the first TAK-881 infusion in study TAK-881-3002, the interval and/or the dose may be adjusted only at scheduled site visits at the investigator's discretion.
Kezelés: TAK-881 és Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- Long-term Safety and Tolerability of TAK-881 in Subjects With Primary Immunodeficiency Diseases (PIDD)
- A regiszteradat frissítve
- 2026. április 8.